Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials

Published:2019-01-23 Issue:4 Volume:34 Page:632-642
ISSN:0884-0431
Container-title:Journal of Bone and Mineral Research
language:en
Short-container-title:J Bone Miner Res

Author:

Bouxsein Mary L¹,Eastell Richard²,Lui Li-Yung³,Wu Lucy A⁴,de Papp Anne E⁵,Grauer Andreas⁶,Marin Fernando⁷,Cauley Jane A⁸,Bauer Douglas C⁴⁹,Black Dennis M⁴,

Affiliation:

1. Center for Advanced Orthopedic Studies; Department of Orthopedic Surgery; Beth Israel Deaconess Medical Center and Harvard Medical School Boston MA USA

2. Academic Unit of Bone Metabolism; University of Sheffield; Sheffield UK

3. California Pacific Medical Center; San Francisco; CA USA

4. Department of Epidemiology and Biostatistics; University of California; San Francisco; San Francisco CA USA

5. Merck & Co., Inc.; Kenilworth NJ USA

6. Amgen Inc.; Thousand Oaks CA USA

7. Eli Lilly and Company; Lilly Research Centre; Windlesham UK

8. Department of Epidemiology; Graduate School of Public Health; University of Pittsburgh; Pittsburgh PA USA

9. Department of Medicine; University of California; San Francisco; San Francisco CA USA

Funder

FNIH Bone Quality Project

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jbmr.3641/fullpdf

Reference59 articles.

1. Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective;Bouxsein;J Bone Miner Res,2008

2. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs;Cummings;Am J Med,2002

3. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents;Hochberg;J Clin Endocrinol Metab,2002

4. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis;Black;N Engl J Med,2007

5. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis;Chestnut;J Bone Min Res,2004

Cited by 220 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of denosumab and teriparatide versus oral bisphosphonates to treat postmenopausal osteoporosis: a systematic review and meta-analysis;Frontiers in Endocrinology;2024-09-02

2. Effect of bisphosphonate and denosumab treatment on TBS in Japanese breast cancer patients with AIBL;Journal of Bone and Mineral Metabolism;2024-08-13

3. The relationship between treatment-related changes in total hip BMD measured after 12, 18, and 24 mo and fracture risk reduction in osteoporosis clinical trials: the FNIH-ASBMR-SABRE project;Journal of Bone and Mineral Research;2024-08-04

4. Six months of voluntary alcohol consumption in male cynomolgus macaques reduces intracortical bone porosity without altering mineralization or mechanical properties;Bone;2024-08

5. Goal-directed osteoporosis treatment: ASBMR/BHOF task force position statement 2024;Journal of Bone and Mineral Research;2024-07-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3